RxDoctor Payments DataLook up a doctor →

Michael Crandall, MD

Dermatology · Phoenix, AZNPI 1780863092

Payments from drug & device makers

$152,674in general payments, 2019–2025

Across 1,155 payments — averaging $132.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$76K
  • UCB, Inc.$48K
  • LEO Pharma Inc.$13K
  • AbbVie$4K
  • Johnson & Johnson$2K
  • Sun Pharmaceutical Industries Inc.$2K
  • plus $8K from 37 others

What the payments were for

  • Consulting fees$8,4136%
  • Speaking & faculty fees$112,58674%
  • Travel & lodging$9,6286%
  • Food & beverage$21,49514%
  • Education$5530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,674 in reported general payments places this provider in the 90th percentile of 305 dermatology providers in Arizona.

See all dermatology providers in Arizona

Medicare billing

Part B allowed, 2024
$754,634
Medicare patients
1,186
Services billed
7,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab20$269,803
OtezlaApremilast42$217,173
OdomzoSonidegib Phosphate13$178,566
Taltz AutoinjectorIxekizumab17$116,037
Dupixent SyringeDupilumab31$114,352
Dupixent PenDupilumab28$114,029
Cosentyx Sensoready (2 Pens)Secukinumab12$111,699
Clobetasol Propionate254$12,775
Fluorouracil135$10,365
Doxycycline Hyclate595$4,922
Triamcinolone Acetonide343$3,344
Ketoconazole172$2,852
Metronidazole46$2,269
Acitretin11$2,001
ValacyclovirValacyclovir Hcl29$1,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,698$269,80320 claims
AmgenOtezla$1,483$217,17342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 305 dermatology providers in Arizona.

Other dermatology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →